1Hull CK, Penman AD, Smith CK, et al. Quantification of rosuvastatin in human plasma by automated solidphase extraction using tandem mass spectrometric detection.J Chromatogr B Analyt Technol Biomed Life Sci, 2002, 772: 219-228.
2Davidison MH. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidemia. Expert Opin Investig Durgs, 2002,11 : 125-141.
3Stein EA. Managing dyslipidemia in the high-risk patient. Am J Cardiol,2002,7:89:50c-57c.
4Paoletti R, Fahmy M, Mahla G, et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemia patients: a randomized, double-blind study. J Cardiovasc Risk,2001,8:383-390.
5Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin in patients with type Ⅱa or Ⅱb hypercholesterolemia. Am J Cardiol, 2002,89:268-275.
6Schuster H. High risk/high priority:familial hyper cholesterole a paradigm for molecular medicine. Atheroscler Suppl, 2002,2: 27-32.
7Chong PH, Yim BT. Rosuvastatin for the treatment of patients with hypercholesterolemia. Ann Pharmacother,2002,36:93-101.
8Laufs U,Gertz K, Dimagl U,et al. Rosuvastatin,a new MHG-CoA reductase inhibitor, uprequlates endothelial nitric oxide synthase and protects from schemic stroke in mice. Brain Rea,2002,28,942:23-30.
9La Rosa JC,He J, Vupputuri HS.Effect of statin on risk of coronary disease:Ameta-analysis of randomized controlled trials. JAMA, 1999,282:2340-2346.
10Auerbach BJ,Dash D, Bousley D, et al.The ACAT inhibitor, avasimibe, reduces aortic cholesterol content in apoE knockout mice, independent of its plasma hypocholesterolemic effects. Atherosclerosis, 2000, (5) :65.
3Hull CK,Penman AD,Smith CK,et al.Quantification of rosuvastatin in human plasma by automated solidphase extraction using tandem mass spectrome tricdetection[J].J Chromatogr B Analyt Technol Biomed Life Sci,2002,772:219.
4Lafus U,Gertz K,Dimagl U,et al.Rosuvastatin,a new HMG-CoA reductase inhibitor,uprequlates endothelial nitric oxide synthase and protects from schemic stroke in mice[J].Brain Res,2002,28,942:23-30.
5Watanabe M,Koike H,Ishiba T,et al.Synthesis and biological activity of methane sulfonamide pyrimidine-and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates,a novel series of HMG-CoA reductase inhibitors[J].Bioorg Med Chem,1997,5:437-444.
7Kumar,Yutendra.Process for the preparation of Rosuvastatin[P].WO:03 097 614,2003-01-23.
8Kamaljit Singh,Jasbir Singh,Prasant K Deb,et al.An expedient protocol of the Biginelli dihydropyrimidine synthesis using carbonyl equivalents[J].Tetrahedron,1999,55:12873-12880.
9C OLIVEER Kappe.Recent advances in the Biginelli dihydropyrimidine synthesis:new tiricks from an old dog[J].Acc Chem Res 2000,33:879-888.
10M Shamim akhtar,M Seth,A PBHADU RI.Synthesis of 2,3-dihydro-5H-thiazolo[3,2-a]pyrimidines & tetrasubstituted dihydropyrimidine derivatives as anthelmintic agents[J].Indian J.Chem,1997,26B:556-567.
